{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:15:01Z","timestamp":1769584501324,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.beha.2018.07.004","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T09:17:52Z","timestamp":1530609472000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA"],"prefix":"10.1016","volume":"31","author":[{"given":"Christopher","family":"Melani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2018.07.004_bib2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2018.07.004_bib3","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.beha.2018.07.004_bib5","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2018.07.004_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9873","key":"10.1016\/j.beha.2018.07.004_bib8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"10044","key":"10.1016\/j.beha.2018.07.004_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2018.07.004_bib10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2018.07.004_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.beha.2018.07.004_bib15","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography--an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLML.2010.n.056","article-title":"Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?","volume":"10","author":"Shenoy","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ejrad.2014.02.015","article-title":"Estimated radiation exposure and cancer risk from CT and PET\/CT scans in patients with lymphoma","volume":"83","author":"Guttikonda","year":"2014","journal-title":"Eur J Radiol"},{"issue":"13","key":"10.1016\/j.beha.2018.07.004_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2014.58.5729","article-title":"Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission","volume":"33","author":"Huntington","year":"2015","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.beha.2018.07.004_bib19","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.beha.2018.07.004_bib20","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","article-title":"Routine imaging for diffuse large B-Cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study","volume":"33","author":"El-Galaly","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2015.01.039","article-title":"Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era","volume":"92","author":"Hiniker","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00277-010-1044-8","article-title":"The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma","volume":"90","author":"Goldschmidt","year":"2011","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.004_bib23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00277-012-1508-0","article-title":"Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas","volume":"91","author":"Lin","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clml.2013.08.009","article-title":"Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission","volume":"14","author":"Truong","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.beha.2018.07.004_bib25","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/annonc\/mdq215","article-title":"Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors","volume":"21","author":"Thompson","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.beha.2018.07.004_bib26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","article-title":"Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas","volume":"83","author":"Rimokh","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00019606-199203000-00005","article-title":"Detection of rearrangements of the BCL2 major breakpoint region in follicular lymphomas. Correlation of polymerase chain reaction results with Southern blot analysis","volume":"1","author":"Ladanyi","year":"1992","journal-title":"Diagn Mol Pathol"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/modpathol.3880556","article-title":"A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas","volume":"15","author":"Belaud-Rotureau","year":"2002","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.beha.2018.07.004_bib29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9440(10)64905-X","article-title":"High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection","volume":"160","author":"Albinger-Hegyi","year":"2002","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2353\/jmoldx.2007.070038","article-title":"\u201cMinor\u201d BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases","volume":"9","author":"Weinberg","year":"2007","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib31","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.beha.2018.07.004_bib32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.beha.2018.07.004_bib34","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"364","key":"10.1016\/j.beha.2018.07.004_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.beha.2018.07.004_bib38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V124.21.392.392","article-title":"Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-Cell lymphoma (DLBCL) in British Columbia (BC)","volume":"124","author":"Sehn","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2018.07.004_bib39","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.beha.2018.07.004_bib40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.beha.2018.07.004_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-006-0151-z","article-title":"FDG-PET\/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease","volume":"85","author":"Querellou","year":"2006","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","article-title":"Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)","volume":"170","author":"Swinnen","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib43","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib44","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.25579","article-title":"Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma","volume":"117","author":"Zinzani","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab","volume":"30","author":"Safar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2018.07.004_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","author":"Duhrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2018.07.004_bib47","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2018.07.004_bib48","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2018.07.004_bib49","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2018.07.004_bib50","first-page":"188","article-title":"Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R","volume":"130","author":"Roschewski","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2018.07.004_bib51","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3109\/10428194.2013.784967","article-title":"Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma","volume":"54","author":"Dabaja","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.116.173542","article-title":"18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab","volume":"58","author":"Lamonica","year":"2017","journal-title":"J Nucl Med"},{"issue":"35","key":"10.1016\/j.beha.2018.07.004_bib53","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13420","article-title":"Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis","volume":"170","author":"Adams","year":"2015","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.beha.2018.07.004_bib55","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib58","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/annonc\/mdl049","article-title":"Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population","volume":"17","author":"Liedtke","year":"2006","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2018.07.004_bib59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3109\/10428194.2011.639882","article-title":"High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database","volume":"53","author":"Abel","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2018.07.004_bib60","series-title":"NCCN clinical practice guidelines in oncology: B-Cell lymphomas","year":"2018"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2013.338","article-title":"Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy","volume":"109","author":"Cheah","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2018.07.004_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/10428194.2010.547642","article-title":"Efficacy of routine surveillance with positron emission tomography\/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center","volume":"52","author":"El-Galaly","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2018.07.004_bib63","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3109\/10428194.2014.900761","article-title":"Clinical impact of contrast-enhanced computed tomography combined with low-dose (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography on routine lymphoma patient management","volume":"55","author":"Chalaye","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23423","article-title":"Strikingly high false positivity of surveillance FDG-PET\/CT scanning among patients with diffuse large cell lymphoma in the rituximab era","volume":"88","author":"Avivi","year":"2013","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/annonc\/mdn629","article-title":"High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens","volume":"20","author":"Han","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10428194.2014.910656","article-title":"The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review","volume":"56","author":"Cheah","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2018.07.004_bib67","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/cam4.322","article-title":"The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma","volume":"4","author":"Nagle","year":"2015","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18 fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.beha.2018.07.004_bib70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.05.053","article-title":"Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy","volume":"87","author":"Filippi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2016.09.031","article-title":"Positron emission tomography\/computed tomography assessment after immunochemotherapy and irradiation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-Cell lymphoma","volume":"97","author":"Ceriani","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.beha.2018.07.004_bib72","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2018.07.004_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.beha.2018.07.004_bib74","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2018.07.004_bib75","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: a paradigm shift in clinical decision making","author":"Melani","year":"2018","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.beha.2018.07.004_bib76","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2018.07.004_bib77","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692618300392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T04:39:17Z","timestamp":1571546357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692618300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1521692618300392"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2018.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}